Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy
Study Details
Study Description
Brief Summary
The T790M mutation is highly sensitive to osimertinib, which is approved in this setting following failure of gefitinib, erlotinib or afatinib. In contrast to first- and second-generation EGFR TKIs, no predominant resistance mechanism to first-line osimertinib has been clearly defined yet. The most common mechanisms of resistance were c-MET amplification only for 15% of patients and the emergence of the EGFR C797S mutation in 7%, while > 60% of patients were still with no identifiable mechanisms of resistance. As a result, targeted treatment options following first-line osimertinib failure remain limited. Thus, interest on sequential administration of EGFR TKIs in patients with EGFR mutation-positive NSCLC has been growing. So, here in this study, we intend to investigate treatment outcome (TOT) along with the several treatment options starting from the first line EGFR TKI treatment to various second line treatments including 3rd generation TKI and chemotherapy and others.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Cohort A T790M+ patients sequentially treated with osimertinib in cohort A |
Drug: Gilotrif
This is non-interventional, multi-center, multi-cohort study based on existing data from EGFR sensitizing mutation-positive NSCLC patients treated with afatinib as the first-line treatment. Enrolled patients will be categorized into four cohorts (cohort A, B, C and D) according to the type of second line treatment with biopsy results before start of second line treatment.
|
| Cohort B T790M- patients treated with chemotherapy or other treatments in cohort B |
Drug: Gilotrif
This is non-interventional, multi-center, multi-cohort study based on existing data from EGFR sensitizing mutation-positive NSCLC patients treated with afatinib as the first-line treatment. Enrolled patients will be categorized into four cohorts (cohort A, B, C and D) according to the type of second line treatment with biopsy results before start of second line treatment.
|
| Cohort C patients with unknown mutation status in cohort C |
Drug: Gilotrif
This is non-interventional, multi-center, multi-cohort study based on existing data from EGFR sensitizing mutation-positive NSCLC patients treated with afatinib as the first-line treatment. Enrolled patients will be categorized into four cohorts (cohort A, B, C and D) according to the type of second line treatment with biopsy results before start of second line treatment.
|
| Cohort D Cohort D included patients who were still ongoing with afatinib. |
Drug: Gilotrif
This is non-interventional, multi-center, multi-cohort study based on existing data from EGFR sensitizing mutation-positive NSCLC patients treated with afatinib as the first-line treatment. Enrolled patients will be categorized into four cohorts (cohort A, B, C and D) according to the type of second line treatment with biopsy results before start of second line treatment.
|
Outcome Measures
Primary Outcome Measures
- Total TOT [Non-interventional study (NIS) based on the existing data from patients' medical records(2013-08-01 ~ 2029-04-30).]
the time on treatment (total TOT) of EGFR M+ NSCLC patients treated with afatinib in the first-line (TOT-1) followed by second line treatments(TOT-2) including osimertinib, chemotherapy and other treatments.
Secondary Outcome Measures
- objective response rate (ORR-1 & ORR-2's) [Non-interventional study (NIS) based on the existing data from patients' medical records(2013-08-01 ~ 2029-04-30).]
- overall survival time [Non-interventional study (NIS) based on the existing data from patients' medical records(2013-08-01 ~ 2029-04-30).]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age more than 18 years
-
Stage IIIB/IIIC/IV/IVA/IVB NSCLC patients treated with first-line afatinib for EGFR sensitizing mutations (Del19, L858R, G719X, S768I, or L861Q etc.)
-
Afatinib treatment was started 13 month prior to data collection date to reduce premature censoring of patients. Data cutoff date will be determined before data entry starts.
Exclusion Criteria:
-
Patients who received drug(s) other than afatinib (Giotrif®) as the first-line treatment
-
Patients who received drug(s) other than 3rd-generation EGFR TKI osimertinib as the second-line in "Cohort A'
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Jin Hyoung Kang | Seoul | Korea, Republic of | 06591 |
Sponsors and Collaborators
- Seoul St. Mary's Hospital
- Boehringer Ingelheim
Investigators
- Study Chair: Jin Hyoung Kang, Seoul St. Mary's Hospital, The Catholic University of Korea
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- TOAST